Drug Profile


Latest Information Update: 28 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Oncology
  • Developer Baxter Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents; DNA inhibitors; Immunomodulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neoplastic meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lymphomatous meningitis; Neoplastic meningitis

Most Recent Events

  • 03 Dec 2003 Discontinued - Phase-II for Neoplastic meningitis in Germany (Intrathecal)
  • 31 May 2000 Phase-II clinical trials for Neoplastic meningitis in Germany (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top